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CBackground: Clopidogrel’s effectiveness is likely reduced significantly
for prevention of thrombotic events after acute coronary syndrome (ACS)
in patients exhibiting a decreased ability to metabolize clopidogrel into its
active form. A genetic mutation responsible for this reduced effectiveness
is detectable by genotyping. Ticagrelor is not dependent on gene-based
metabolic activation and demonstrated greater clinical efficacy than
clopidogrel in a recent secondary prevention trial. In 2011, clopidogrel will
lose its patent protection and likely will be substantially less expensive
than ticagrelor. Objective: To determine the cost-effectiveness of ti-
cagrelor compared with a genotype-driven selection of antiplatelet
agents. Methods: A hybrid decision tree/Markov model was used to es-
imate the 5-year medical costs (in 2009 US$) and outcomes for a cohort of
CS patients enrolled in Medicare receiving either genotype-driven or
icagrelor-only treatment. Outcomes included life years and quality-ad-
usted life years (QALYs) gained. Data comparing the clinical performance
f ticagrelor and clopidogrel were derived from the Platelet Inhibition and O
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doi:10.1016/j.jval.2010.11.012atient Outcomes trial. Results: The incremental cost-effectiveness ratio
ICER) for universal ticagrelor was $10,059 per QALY compared to geno-
ype-driven treatment, and was most sensitive to the price of ticagrelor
nd the hazard ratio for death for ticagrelor compared with clopidogrel.
he ICER remained below $50,000 per QALY until a monthly ticagrelor
rice of $693 or a 0.93 hazard ratio for death for ticagrelor relative to clopi-
ogrel. In probabilistic analyses, universal ticagrelor was below $50,000
er QALY in 97.7% of simulations. Conclusion: Prescribing ticagrelor uni-
ersally increases quality-adjusted life years for ACS patients at a cost
elow a typically accepted threshold.
eywords: acute coronary syndrome, clopidogrel, cost-benefit analysis,
econdary prevention, ticagrelor.
opyright © 2011, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Current American and European guidelines recommend dual
antiplatelet therapy with aspirin and clopidogrel for at least 1
month and optimally 1 year for all acute coronary syndrome
(ACS) patients to reduce the risk of recurrent thrombotic events
[1– 4]. Clinical trials indicate that when added to aspirin follow-
ing ACS, clopidogrel is effective at reducing the risk of repeat
ischemic episodes, heart failure, and revascularization proce-
dures [5–7]. Although it remains part of the current recom-
mended treatment after ACS, clopidogrel has substantial limi-
tations. Because it irreversibly inactivates platelets its effect is
not eliminated until the patient replaces his/her platelet supply.
Clopidogrel administration has been associated with increased
bleeding following coronary artery bypass surgery (CABG), and
the current American guidelines currently recommend a 5-day
waiting period prior to elective surgical procedures due to this
complication [8 –12]. The frequent need for emergent CABG in
the ACS population has led to controversy about the safety of
the procedure in the setting of clopidogrel exposure [13]. A more
* Address correspondence to: Joseph S. Rossi, MD, Division of C
Building 6036, CB# 7075, 160 Dental Circle, Chapel Hill, NC 27599-7
E-mail: joseph_rossi@med.unc.edu.
1098-3015/$36.00 – see front matter Copyright © 2011, Internation
Published by Elsevier Inc.important limitation of clopidogrel is that in some patients it
may fail to inactivate platelets when given at therapeutic doses
[14]. Extensive genetic analyses targeting both the P2Y12 recep-
or and the enzymes that metabolize clopidogrel into its active
orm have been conducted [15–26]. Attention has focused on
utations in the gene encoding CYP2C19 (a P450 hepatic en-
yme), which have been shown to reduce clopidogrel’s effec-
iveness both in vitro and in healthy volunteers [16,20,25]. Ob-
servational clinical studies have shown that patients with a
CYP2C19*2 mutation have approximately a 50% higher likeli-
hood of adverse cardiac outcomes than patients without such
mutation, but only when patients are treated with clopidogrel
[27–31]. This result strongly suggests that the mutation’s effects
are mediated through its effects on clopidogrel activation.
These mutations are very common; with estimates of the prev-
alence of at least a single copy of the mutation ranging from 20%
in white populations to 50% in some Asian groups [27,32].
Trial results for ticagrelor, a novel antiplatelet agent, have
been promising. Among patients admitted with ACS, adminis-
tering 90 mg ticagrelor twice daily reduced both rates of recur-
ology, University of North Carolina Hospitals, Burnett-Womack
USA.
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
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484 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 4 8 3 – 4 9 1rent cardiac events and all-cause mortality without increasing
the risk of major bleeding compared to standard dose clo-
pidogrel [33]. Furthermore, ticagrelor is not dependent on met-
abolic activation and its mechanism of action is reversible, giv-
ing a faster elimination of effect upon withdrawal [34]. The
platelet inhibition levels of clopidogrel patients after 5 days of
withdrawal have been observed in ticagrelor patients just 3 days
post withdrawal [35]. However, ticagrelor is associated with an
increased risk of minor bleeding compared to clopidogrel [33].
The patent on the branded formulation of clopidogrel, Pla-
vix™ (Sanofi-Aventis, Bridgewater, NJ), is scheduled to expire in
011; consequently, the cost of generic clopidogrel, currently
131 per month at retail prices in the United States, is likely to
all substantially [36]. Given its expected low cost in the near
uture, clopidogrel will likely continue to be a feasible option for
ntiplatelet therapy, particularly for patients without a de-
reased ability to metabolize clopidogrel into its active form.
herefore, providers will likely have a choice in treatment op-
ions for choosing antiplatelet therapy for ACS. We developed a
ost-effectiveness study comparing two likely strategies for
reating ACS: 1) a genotype-driven treatment, in which provid-
rs test for CYP2C19*2 mutations that limit clopidogrel’s effec-
iveness and prescribe clopidogrel in their absence and ticagre-
or in their presence, and 2) universally prescribe ticagrelor.
his analysis was conducted from the viewpoint of Medicare, as
atients of age 65 and older experience over half of all ACS cases
37]. Although economic evaluations have been used to deter-
ine clopidogrel’s role in secondary prevention after ACS
38,39], to the best of our knowledge no studies have been pub-
ished to date evaluating the cost-effectiveness of ticagrelor
ersus clopidogrel. Private payers and integrated health deliv-
ry systems will need to weigh the inexpensive pharmaceutical
osts of a genotype-based strategy centered on generic clo-
idogrel against the incremental clinical benefits of ticagrelor.
Methods
Model cohort
In order to capture relatively small monthly rates of events, we de-
veloped our model with a population of 100,000 Medicare beneficia-
ries of age 66 or older hospitalized for ACS. We used 66 as the starting
age of the cohort to allow for 1 year of claims data to apply exclusion
criteria in the process of generating mortality and repeat myocardial
infarction (MI) hazard rates. The analysis population differs some-
what from the Platelet Inhibition and Patient Outcomes (PLATO) trial
cohort, which included adults hospitalized with any form of ACS,
with the exception of ST-elevation myocardial infarction (STEMI)
treated by fibrinolysis [40]. Because our model hazard rate ratios are
erived from the PLATO study our model is most applicable to pa-
ients who meet the study’s entry criteria, which includes having no
ontraindication to clopidogrel, need for anticoagulation therapy,
se of a CYP3A inhibitor, dialysis dependence, thrombocytopenia, or
nemia. Our model population was older than the median PLATO
articipant (mean age 79 vs. 62 years old); No heterogeneity in treat-
ent response by age was observed in the PLATO cohort [33].
Model structure
We used a hybrid decision tree/Markov model to analyze the cost-
effectiveness of genotype-driven antiplatelet therapy for ACS. As
presented in the decision tree in Figure 1, our model allowed provid-
ers two choices for ACS treatment: 1) genotype-driven treatment,
and 2) universal ticagrelor. For genotype-driven treatment each pa-
tient is tested for CYP2C19*2 mutations and prescribed clopidogrel in
their absence and ticagrelor in the presence of any CYP2C19*2
mutation. We created a Markov model to estimate the outcomesfor each treatment option using 1-month cycles as presented in
Figure 2. The Markov model included events that were shown to
have statistically and clinically significant differences between
ticagrelor and clopidogrel in the PLATO study, which included
MI, dyspnea, and all-cause mortality [33]. Although overall rates
of major or minor bleeding were not significantly different be-
tween ticagrelor and clopidogrel patients in the PLATO study we
accounted for major or minor bleeding in the model because the
rates of bleeding were significantly different for major bleeding
not related to CABG and for fatal intracranial bleeding [33]. Be-
cause the effectiveness of ticagrelor is independent of the
CYP2C19*2 mutation, we assumed ticagrelor response to be the
same for patients of all genotypes [41].
Two general Markov states are used in the model: 1) post-ACS
event and 2) deceased. During each month’s cycle a patient was at
risk for MI, bleeding, dyspnea, or death due to any cause. All events
were assumed to be independent of one another. Quality-adjusted
life years (QALYs) were accumulated during each cycle and were
adjusted for time since last ACS event. Adjustments for bleeding
and dyspnea were made only in the month that the complication
occurred. Medical costs were experienced during the month of the
event and subsequent care costs, excluding those for recurrent MI
and bleeding, were incurred in the month of an ACS event and
lasted until the lesser of 12 months or death. We assumed patients
were prescribed antiplatelet medication for the first 12 months
after the initial ACS event and after any subsequent MI. We al-
Fig. 1 – Decision tree outlining treatment options under
comparison. Patients either receive CYP2C19*2 mutation
testing and have antiplatelet therapy selected by testing
result or receive ticagrelor without genetic testing.lowed rates of all-cause mortality, MI, and bleeding to be equal
485V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 4 8 3 – 4 9 1between the two treatment options beyond the 12 months of an-
tiplatelet therapy; thus survival of the two treatment options con-
verge over time. Patients had no risk of dyspnea in either treat-
ment strategy when not undergoing antiplatelet therapy. All costs
and outcomes were discounted at an annual rate of 3%, with sen-
sitivity analysis performed for rates of 0 to 5% [42].
Model probabilities
The probabilities, hazard rates, and hazard rate ratios used to cal-
culate transitions probabilities incorporated into the decision
model are listed in Table 1 and Supplementary Table 1 available at:
doi:10.1016/j.jval.2010.11.012. The probability of CYP2C19*2 muta-
tion was obtained by weighting ethnicity-specific estimates by the
ethnic composition of the Medicare program; because ethnicity
was categorized as white, black, Hispanic, and other, all patients
identified as other were assumed to be Asian [43–47]. The utility/
usefulness of historical estimates of long-term survival after ACS
is limited by recent reductions in mortality due to improvements
in ACS care and in risk factors [48]. We responded by generating
novel hazard rates for mortality, repeat myocardial infarction, and
bleeding risk in a contemporary cohort of Medicare beneficiaries.
We identified all Medicare patients 66 years old and older admit-
ted to a hospital with an International Classification of Diseases,
9th edition, Clinical Modification (ICD-9-CM) diagnosis code for
ACS, either myocardial infarction (410.xx) or unstable angina
(411.1), between January 1, 2003, and October 15, 2004. We used
inpatient claims data from the 2003-2007 Medicare Provider and
Analysis File as well as Medicare Denominator files to evaluate
patients for up to 5 years after ACS admission, using censoring to
account for patients with shorter follow-up durations. This
claims-based analysis received approval from the Institutional Re-
view Board at the University of North Carolina at Chapel Hill.
Because MI is a transitory state, its risk was modeled using a
repeated risk framework [49]. The Supplementary Appendix
(found at: doi:10.1016/j.jval.2010.11.012) describes the methodol-
ogy used to develop our hazard rate estimates in more detail. The
PLATO trial did not individualize therapy based on genotype, so it
likely underestimates the performance of clopidogrel in a geno-
type-directed strategy because some patients with CYP2C19*2 mu-
tations would have been randomized to receive clopidogrel. We
assumed these patients received no benefit from clopidogrel and
used data from the Clopidogrel in Unstable Angina to Prevent Re-
current Events trial (CURE) [5] (which compared clopidogrel with
placebo) to adjust the hazard rates according to Equation 1.
RateAdjRateUnadj ⁄ (P(wild type) P(mutation) * riskplacebo ⁄ riskclopidogrel)
Fig. 2 – Markov model. During each month-long cycle,
patients may experience repeat MI, bleeding, dyspnea, or
death. Transition probabilities adjust to reflect patient age
and choice of antiplatelet treatment. ACS, acute coronary
syndrome; MI, myocardial infarction.(Eq 1)In all cases, when probabilities were adjusted to change cycle
length they were first converted to instantaneous rates [50].
Ranges were calculated as 95% confidence intervals to reflect
the degree of uncertainty in the source data [5,33,42– 47,51– 65].
Analytical perspective
This analysis was conducted from the perspective of Medicare,
which is the primary health insurance provider for virtually all US
citizens 65 years old and older [66]. Although patient cost sharing
is not explicitly included within the model, the range provided for
the costs of the antiplatelet medications indirectly allows for sub-
stantial pharmaceutical copayments. Until recently this perspec-
tive would have excluded most outpatient prescription medica-
tions, but the advent of Medicare Prescription Drug Plans (PDPs)
has meant that such costs are now within Medicare’s scope. Costs
were included only if they directly relate to the provision of med-
ical services and thus accrue to the Medicare budget. We assume
reimbursements based on traditional Medicare Parts A and B and
do not account for differences in reimbursement resulting from
enrollment in Medicare Advantage or private, fee-for-service
plans.
Cost estimates
Table 1 presents the costs for each resource used after ACS
diagnosis. All costs are in 2009 US dollars and were inflated
using the Medical Care Component of the Consumer Price Index
when necessary [67,68]. Genotype tests to determine whether a
patient has CYP2C19*2 mutations, although not yet widely
available throughout the either North American or European
settings, recently have been offered for the first time in the
United States [69]. Initial reports place the price of the test at
approximately $200, which represents the complete cost to the
payer for the laboratory service and not simply the marginal
cost of processing the test [54]. We assumed that the genotyping
assay utilizes a buccal swab rather than blood for DNA collec-
tion, which can be self-administered and thus we excluded
costs for obtaining a sample. This assumption underestimates
the cost of the genotype-driven treatment if some institutions
utilize blood testing. We assumed each patient received this
test one time, simultaneously with their index ACS diagnosis,
and that the test had both 100% sensitivity and specificity.
These assumptions likely bias our results in favor of the geno-
type-driven therapy.
Pricing data are not currently available for ticagrelor or ge-
neric clopidogrel. We assumed the price of a 1-month’s supply
(i.e., 30 75-mg tablets) of generic clopidogrel to be $30. This
estimate is consistent with the projected price used in a previ-
ous cost-effectiveness analysis of prasugrel versus clopidogrel
[70]. We assumed the price of ticagrelor to be the same as the
net wholesale price of prasugrel. Prasugrel’s manufacturers, Eli
Lilly & Co and Daiichi Sankyo Co, have initially priced the drug
at approximately $164 for a 1-month supply of 30 10-mg tablets
[71].
We searched both the cost-effectiveness analysis (CEA) reg-
istry at Tufts University and the National Institute of Health’s
PubMed database for MI and bleeding hospitalization costs for
Medicare patients. The direct medical costs of MI and bleeding
events were assumed to be the same for both treatment options.
We used event costs of $18,390 for non-fatal MI and $16,093 for
fatal MI, derived from the frequency of Medicare diagnosis-
related group hospital payments in the Agency for Healthcare
Research and Quality’s nationwide inpatient sample [62]. For
the purposes of costing and health-related quality of life
(HRQOL) adjustment, we assumed that all cases of bleeding
were gastrointestinal (GI) bleeding. The base-cost for bleeding
was estimated to be $7491 [55,56,58]. This estimate is equivalent
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ost-effectiveness analysis of clopidogrel versus placebo. We
hen obtained subsequent care costs for all ACS patients, ex-
luding those costs for recurrent MI, that were derived from
Table 1 – Model inputs used in comparison of antiplatelet
Parameter Bas
Probability of mutation 0
Hazard rate of death (by month)
1 0
2 0
3 0
4 0
5 0
6 0
7–60
Hazard rate of MI (by month)
1 0
2 0
3 0
4 0
5 0
6 0
7–60
Hazard rate of bleeding (by month)
1 0
2 0
3 0
4 0
5 0
6 0
7–60
Probability of dyspnea (monthly) 0
Hazard rate ratios
Clopidogrel vs. placebo
Death 0
MI 0
Bleeding 1
Ticagrelor vs. clopidogrel
Death 0
MI 0
Bleeding 1
Dyspnea 1
Costs*
Genotype test† $2
Medication‡
Generic clopidogrel $3
Ticagrelor $1
ACS event costs
Fatal MI $1
Non-fatal MI $1
Bleeding $7
Subsequent monthly ACS care‡ $3
Baseline utility weight 0
Event-related utility tolls
MI (first year) 0
MI (subsequent years) 0
Death 0
GI bleeding (utility toll during month of event) 0
Dyspnea (at any time during treatment) 0
ACS, acute coronary syndrome; GI, gastrointestinal; MI, myocardial i
* Costs are expressed in 2009 US dollars.
† One-time cost for all patients in genotyping arm.
‡ Cost incurred every month for 1-year after ACS event.requency of acute care procedures present in the nationwide unpatient sample and using costs from the Medicare physician
ee schedule [62]. We then excluded bleeding costs to estimate
ubsequent ACS care costs of $356 per month. We attributed no
irect medical costs for dyspnea as we assumed dyspnea to be
egies after ACS.
se Range Reference
(0.1831–0.3839) [43–47]
(0.2052–0.2075) This study
(0.0468–0.0479)
(0.0284–0.0294)
(0.0220–0.0228)
(0.0181–0.0189)
(0.0162–0.0169)
See Supplemental Table 1
(0.0269–0.0277) This study
(0.0179–0.0187)
(0.0119–0.0125)
(0.0100–0.0105)
(0.0085–0.0091)
(0.0074–0.0079)
See Supplemental Table 1
(0.0931–0.0947) This study
(0.0131–0.0137)
(0.0095–0.0101)
(0.0081–0.0086)
(0.0070–0.0075)
(0.0067–0.0072)
See Supplemental Table 1
(0.0731–0.0841) [33]
(0.78–1.06) [5]
(0.67–0.89) [5]
(1.47–1.94) [5]
(0.68–0.89) [33]
(0.74–0.95) [33]
(1.07–1.16) [33]
(1.68–2.02) [33]
($100–$300) [54]
($15–$45) [70]
($100–$300) Assumed
($6902–$48,999) [62]
($6040–$42,879) [62]
($2862–$19,606) [55, 56, 58]
($156–$1109) [62]
(0.83–0.87) [59]
(0.80–0.96) [60–62]
(0.80–0.95) [60–62]
N/A [42]
(0.50–1.00) [61, 63, 64]
(0.47–1.00) [65]
tion.strat
e ca
.2835
.2063
.0474
.0289
.0224
.0185
.0165
.0273
.0183
.0122
.0103
.0088
.0077
.0939
.0134
.0098
.0083
.0073
.0069
.0785
.91
.77
.69
.78
.84
.11
.84
00
0
64
6,093
8,390
491
56
.85
.87
.91
.75
.93
nfarcntreated in our sample; although more patients discontinued
r.
487V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 4 8 3 – 4 9 1ticagrelor due to dyspnea than clopidogrel (0.9% vs. 0.1%), we
viewed the absolute number as small enough to justify not mod-
eling as part of this analysis.
Outcomes
We reported outcomes in terms of QALYs and life years gained.
The cohort’s baseline utility values were obtained from a nation-
ally representative survey of non-institutionalized Americans uti-
lizing the EuroQol five-dimensional (EQ-5D) questionnaire [59]. We
obtained baseline utility values of 0.86 for 66- to 74-year-olds and
0.84 for 75- to 95-year-olds and then used their average value (0.85)
as our baseline utility value. We searched the CEA Registry to lo-
cate utility weightings for each outcome state within the model,
limiting results to reports on American patient populations pub-
lished since 1998 [72]. From this literature we derived HRQOL mul-
tiplicative adjustments of 0.87 in the first year post-MI and 0.91 in
subsequent years. ACS includes unstable angina, which is not a
form of MI; however, European evidence suggests that unstable
angina causes an equivalent reduction in HRQOL [73]. Because of
the unclear external validity of this measure we enlarged the stan-
dard errors of our estimates; our range included all point estimates
listed within the CEA registry for myocardial infarction without
other comorbidities specified. GI bleed was estimated to have a
utility toll equivalent to one quality-adjusted life-week. We there-
fore used a monthly HRQOL adjustment of 0.75, the equivalent of 1
week’s utility. We assumed in the absence of additional informa-
tion that the dyspnea experienced by the trial subjects is mild, as
only 8% of subjects who experienced dyspnea during the PLATO
trial stopped taking ticagrelor for that reason. Thus, we assumed
that the dyspnea experienced by trial subjects is, at worst, equiv-
alent to Global Initiative for Chronic Obstructive Lung Disease
stage I disease, which corresponds to a mild decline in respiratory
function as measured by spirometry [74]. Chronic obstructive pul-
monary disease was selected over asthma because of the more
episodic nature of the latter condition. Using this information we
derived an estimated HRQOL adjustment of 0.93 from the relevant
literature. As is customary, we assigned death a utility weight
of 0 [42].
Sensitivity analyses
To determine the sensitivity of our model to uncertainty within the
input variables, we conducted one-way analysis by varying parame-
ters individually and reporting the resulting incremental cost-effec-
tiveness ratios (ICERs). Because of the large number of input param-
eters included, only parameters that altered the ICER by more than
$1500 are reported. We also varied the model length and discount
rate to determine whether the analytic horizon affected the base-
case results. Because some patients may receive treatment for peri-
ods longer than 12 months, we also simulated 15- and 24-month
therapy durations. Threshold analysis was conducted to determine
both the cost-effective threshold for the price of ticagrelor and the
Table 2 – Case cost-utility analysis of antiplatelet strategie
Cost* Outcome (QALYs
After 1 year
Genotype-driven $713,983,854 56,603
Universal ticagrelor $794,382,109 58,492
After 5 years
Genotype-driven $943,144,383 217,711
Universal ticagrelor $1,047,138,812 228,049
ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted lif
* Cost are expressed in 2009 US dollars and discounted at 3% per yeahazard rate ratio for mortality between ticagrelor and clopidogrel. Todetermine whether the joint uncertainty of model parameters af-
fected the model results, we conducted probabilistic sensitivity anal-
ysis using Monte Carlo simulation (1000 iterations). Transition prob-
abilities and the utility of health states were generally modeled using
beta distributions, using count data from trials when available and
method of moment approximations otherwise [50]. Beta distribution
parameters were specified using median, maximum, alpha and beta
parameters to ensure sampling distributions were centered at the
base-case estimate. Most hazard rates, hazard rate ratios, and costs
were modeled using log-normal or normal distributions [50]. Because
the costs of genotyping, generic clopidogrel, and ticagrelor have not
been established, we modeled these parameters as triangular distri-
butions, with minimum and maximum values prespecified as 50%
and 150% of the point estimate, respectively. All other medical costs
were assumed to follow a log-normal distribution. Results from these
analyses are presented via both the cost-effectiveness plane and
cost-effectiveness acceptability curves. Although an appropriate
cost-effectiveness threshold for American health care purchasers re-
mains a subject of debate, we used the typical accepted US threshold
of $50,000 per QALY as cost-effective [42,75]. Simulations were con-
ducted in Excel 2007 (Microsoft, Redmond, WA) using Crystal Ball,
Fusion Edition version 11.1.1.3 (Oracle, Redwood City, CA). The cost-
effectiveness curves were calculated with SAS version 9.2 (SAS Insti-
tute, Cary, NC) using the net-benefit framework [50].
Results
Base-case results
Providing ticagrelor universally rather than employing genotype-
driven treatment produced 0.10 additional QALYs per person at an
incremental cost of $1040 per person. The ICER was $10,059 per QALY
for a 5-year time horizon, as compared to a genotype-driven treat-
ment option (Table 2). Because the majority of the cost differential
between the two treatments occurs in the first year the ICER reached
its maximum after eleven months of therapy (Fig. 3) and was $42,546
per QALY after 1 year of treatment. We found that the ICER increased
for longer durations of therapy. A 15-month duration of therapy re-
sulted in an ICER of $12,334 per QALY and at 24 months the ICER
increased to $18,682 per QALY. Similar results were obtained in the
analysis of life years gained, as expected given the survival benefit
produced by ticagrelor. The ICER for universal ticagrelor was $7539
per life year compared to the genotype-driven treatment over the
5-year period. On average, universal ticagrelor resulted in 0.14 life
years gained.
One-way sensitivity analysis results (Table 3) indicate that uni-
versal ticagrelor remains a cost-effective intervention across the
probable range of each input parameter. The ICER as predicted by our
model is most sensitive to the price of ticagrelor ($3858– $16,260 per
QALY) and the hazard rate ratio for death for ticagrelor compared
with clopidogrel ($7594– $21,181 per QALY). Threshold analysis cal-
r acute coronary syndrome.
Incremental cost QALYs gained ICER ($/QALY)
— — —
$80,398,255 1890 42,546
— — —
$103,994,429 10,338 10,059
r.s afte
)
e yeaculations indicate that the monthly price of ticagrelor would need to
488 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 4 8 3 – 4 9 1increase from $164 to $693, or the hazard rate ratio for death relative
to clopidogrel increased from 0.78 to 0.93 for the ICER to exceed
$50,000 per QALY. Even in the scenario in which clopidogrel becomes
a deeply discounted generic (costing $4 for a 30-day supply) ticagrelor
retains its cost-effectiveness advantage ($11,927 per QALY). The
model was insensitive to changes in the discount rate when varied
between 0% and 5% ($9641–$10,338 per QALY). To determine whether
the model was sensitive to systematic changes in mortality risk we
modified the baseline mortality risk using a hazard rate ratio from 0.5
to 3.0 and found ticagrelor remained cost-effective across the entire
range ($15,954– $6873 per QALY).
Probabilistic sensitivity analyses demonstrated that univer-
sal ticagrelor is a more costly yet more effective intervention
than genotype-driven therapeutic selection (Fig. 4). The cost-
effectiveness plane illustrates both the magnitude and sign of
the incremental benefits and costs of one treatment over an-
Fig. 3 – The incremental cost-effectiveness ratio (ICER)
calculated as a function of the discounted cumulative costs
and outcomes (QALYs) accrued from initiation of therapy
up to each time period indicated. Thus, this diagram
portrays the effect of different analytical horizons on cost-
effectiveness. In this model, the higher monthly cost of
ticagrelor during the initial 1 year of therapy leads to a
peak ICER of $42,656 (US dollars) per QALY at 11 months
after the initial ACS episode. ACS, acute coronary
syndrome; QALY, quality-adjusted life year.
Table 3 – One-way sensitivity analysis* comparing univers
Inpu
Low H
HR ratio: death (ticagrelor vs. clopidogrel) 0.68 0
Cost: ticagrelor $82 $2
HR ratio: death (clopidogrel vs. placebo) 0.78 1
Cost: subsequent monthly ACS care $156 $1
HR ratio: MI (ticagrelor vs. clopidogrel) 0.74 0
HR ratio: MI (clopidogrel vs. placebo) 0.67 0
Cost: clopidogrel $15 $4
Cost: genotype test $100 $3
HRQOL adjustment: dyspnea 0.47 1
Cost: non-fatal MI $6902 $4
HR, hazard rate; HRQOL, health-related quality of life; ICER, increm
adjusted life year.
* Only parameters that altered the ICER by more than $1500 are reported.other; the slope from the origin to each point indicates the in-
cremental-cost effectiveness ratio for that iteration. In only 1 of
1000 simulations was universal ticagrelor the dominant inter-
vention (less expensive and more effective) and in 12 of 1000 it
was the dominated intervention (more expensive and less ef-
fective). For 977 of the 1,000 simulations, the estimated ICER
was less than the $50,000 per QALY threshold. The cost-effec-
tiveness acceptability curve (Fig. 5) illustrates the probability
that an intervention is cost-effective given a policymaker’s
stated cost-effectiveness threshold (i.e., how much he or she is
willing to pay per additional quality-adjusted life year) [76]. In
this model, policymakers willing to pay $30,200 or more per
QALY would have a 95% chance of being correct in choosing
universal ticagrelor (that ticagrelor would in fact be cost effec-
tive).
Discussion
In a cohort of ACS patients 66 years old or older enrolled in Medi-
care, the cost of universally prescribed ticagrelor is $10,059 per
QALY compared to a genotype-driven alternative over a 5-year
time horizon. On average each patient gains 0.10 QALYs. This cost
is well within the $50,000 per QALY threshold typically used for
health services research in the United States. In probabilistic sen-
sitivity analysis only 2.2% of simulations produced an ICER greater
than $50,000 per QALY. This result signals that ticagrelor’s efficacy
outweighs generic clopidogrel’s likely inexpensive price, even if
the patients for whom clopidogrel is not effective are identified
and receive ticagrelor instead. In shorter analytic horizons univer-
sal ticagrelor is less cost-effective but still within the $50,000 per
QALY threshold. This result is not surprising given that all patients
receive drug therapy during the first year of treatment and pa-
tients prescribed ticagrelor have substantially higher medication
cost than patients prescribed generic clopidogrel. In subsequent
years the number of patients receiving medication is considerably
reduced (only those patients suffering recurrent MI were assumed
to restart dual antiplatelet therapy), decreasing the medication
cost differential of the two treatment options. As expected the
cost-effectiveness of universal ticagrelor is most sensitive to the
hazard rate ratio of death for ticagrelor relative to clopidogrel, as
the major benefit of ticagrelor is reduced mortality. The cost-
effectiveness of universal ticagrelor likely will be reduced if the
magnitude of this benefit is less than that found in the PLATO trial
or if the benefits of clopidogrel are greater than have been ob-
served in clinical trials. In our sensitivity analysis the cost-effec-
agrelor to genotype-driven therapy.
es ICER ($/QALY)
Base Low High Difference
0.78 7594 21,181 13,587
$164 3858 16,260 12,402
0.91 15,743 7951 7792
$354 9298 12,924 3626
0.84 8395 11,890 3495
0.77 11,182 8884 2298
$30 11,137 8982 2154
$200 11,027 9092 1934
0.93 11,685 9851 1834
$18,390 9461 11,245 1784
cost-effectiveness ratio; MI, myocardial infarction; QALY, quality-al tic
t valu
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489V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 4 8 3 – 4 9 1tiveness of universal ticagrelor decreased considerably as the haz-
ard rate ratio approach 1.00 and at 0.93 the ICER surpasses the
$50,000 per QALY threshold. Ticagrelor’s clinical efficacy allows
universal ticagrelor to be cost-effective at prices significantly
higher than generic clopidogrel. Universal ticagrelor is less cost-
efficient than genotype-driven treatment only when the price of
ticagrelor exceeds $693 per month, a price that is unrealistic given
clopidogrel and prasugrel’s branded price of approximately $150
per month.
This study had several limitations. Most notably, our analysis
was based on the efficacy of antiplatelet medication in clinical
trials. The ultimate effectiveness of antiplatelet medication likely
cannot be determined from clinical trial data alone due to their
short duration. Long-term projections should be reviewed with
caution as the clinical trial investigated antiplatelet medication in
much shorter time intervals. Many of the key inputs to our model
were from the PLATO trial, which was 12 months in duration.
Although we estimated the cost-effectiveness of universal ticagre-
lor at duration lengths of 15 and 24 months, our estimates may be
biased if the effectiveness of ticagrelor differs after 12 months of
therapy. Ongoing studies evaluating the efficacy of dual antiplate-
let therapy beyond 12 months will have significant implications on
the long-term cost-effectiveness of clopidogrel and ticagrelor. Due
to selection criteria our results may not apply to subpopulations
excluded from these trials. Particularly, subgroups of the general
ACS population may exhibit different treatment responses that
may affect the cost-effectiveness of any treatment option. Ad-
verse events costs may vary within subpopulations due to events
that significantly differ between ticagrelor and clopidogrel pa-
tients outside of MI, bleeding, and dyspnea. The inclusion of these
costs should be considered when estimating the cost-effective-
ness of universal ticagrelor for other populations. For example,
PLATO patients with a planned invasive treatment strategy were
less likely to experience stent thrombosis when given ticagrelor
compared to clopidogrel (HR0.73, 95% CI 0.59–0.92; p value0.007)
77]. Secondly, we assumed that recurrent MI and death were inde-
endent events. This occurrence is likely unrealistic but was un-
voidable in our model because data from the PLATO trial were pre-
Fig. 4 – Incremental cost-effectiveness plane showing
Monte Carlo estimates of incremental costs and benefits of
using ticagrelor universally for secondary prevention after
ACS versus genotype-based selection of clopidogrel or
ticagrelor. ACS, acute coronary syndrome; QALY, quality-
adjusted life year.ented in a manner that did not make it possible to determine howmany MIs and deaths were not independent events. Because ticagre-
lor remained cost-effective even if no reduction in MI was included in
the model (ICER $10,967 per QALY), we view the impact of this limi-
tation as minor. Lastly, our results cannot be used to determine uni-
versal ticagrelor’s cost-effectiveness relative to other viable treat-
ment options for secondary prevention after ACS. When making
decisions regarding ACS treatment prasugrel should also be consid-
ered; preliminary cost-effectiveness results powered by data from
the TRITON-TIMI trial indicate that prasugrel is cost-effective when
compared to clopidogrel for patients receiving percutaneous coro-
nary intervention for ACS. A comparison of all proposed treatment
strategies would clarify how providers should approach this impor-
tant clinical problem [78]. Controversy continues to grow about the
role of specific genetic mutations, including those within CYP2C19*2,
in affecting outcomes for patients treated with clopidogrel [79,80].
Although our results are robust to a broad range of sensitivity as-
sumptions regarding the prevalence of clopidogrel non-response
and test characteristics, additional analyses will be valuable as alter-
native methods of characterizing clopidogrel response are devel-
oped.
Universal ticagrelor is cost-effective in a cohort of Medicare
beneficiaries hospitalized for ACS when compared to a genotype-
driven alternative. The efficacy of ticagrelor relative to clopidogrel
substantially outweighed the higher medication costs associated
with ticagrelor. Further research is needed to assess the cost-ef-
fectiveness of universal ticagrelor across subpopulations and to
compare the cost-effectiveness of ticagrelor to other ACS treat-
ment options. However, if these results are confirmed they sup-
port the prioritization of ticagrelor over generic clopidogrel for
Medicare beneficiaries; a policy recommendation complicated by
the structure of Medicare. Most Medicare beneficiaries receive
medical benefits from the government but outpatient prescription
coverage through a government-subsidized private PDP. Because
PDPs maximize their profitability by minimizing pharmaceutical
expenditures, PDPs create incentives to prefer generic medica-
tions through co-payment tier arrangements. Complimenting the
incentives to insurers offering PDPs, the use of lower cost generics
is supported by members of Congress eager to reduce budgetary
Fig. 5 – Cost-effectiveness acceptability curve depicting the
probability that using ticagrelor universally for secondary
prevention after acute coronary syndrome versus
genotype-driven selection of clopidogrel or ticagrelor is
cost-effective at different cost-effectiveness thresholds.
The dashed lines indicate the amount a decision maker
should be willing to pay to be 95% certain that the decision
to use ticagrelor universally is cost-effective ($30,200 US
dollars).
([
490 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 4 8 3 – 4 9 1pressures [81,82]. Our findings highlight both the importance of
evaluating the relative value of health care interventions in light of
their cost and the need to develop more nuanced payment models
creating incentives for the provision of affordable, high quality
care.
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